Who's who

3 Houston tech innovators to know this week

Tech startups are popping up across industries from real estate to oil and gas, and these three founders are among the leaders in technology. Courtesy images

Often, technology and innovation are mistaken for each other. While not mutually exclusive, both tech and innovation work well together in Houston across all industries — from oil and gas to real estate and social media. These three founders engaged technology for their individual startups.

Srini Katta, founder and CEO of Social Chains

Courtesy of Social Chains

As a social media user, your data is already out there and being used for marketing purposes. But, rather than the Facebooks or Googles of the world making a profit, Srini Katta wanted to create a platform where users made a profit off their own data.

"On our platform, the user is a stakeholder. Our platform distributes 50 percent of the profits to the users," he says.

Social Chains already has 5,000 users and, Katta says, that's with little to no marketing efforts, which Katta is about to launch.

Martin Kay, founder and CEO of Entera Technology

Courtesy of Entera

Martin Kay, who splits his time between Houston and the Bay Area for his startup Entera Technologies, knew there had to be a better way for people searching for a home to buy. He drew a comparison between homebuyers and Netflix viewers to create Entera's software.

"We're a little bit like Netflix," he says. "They go out and get content from everyone, and they begin to watch your behavior. So, Netflix has 2,000 profiles and you probably fit five or six of those. We have almost 100 profiles and what we do is say, we're going to understand what you want, watch your behavior and instead of giving you 40,000 properties on a big map, we actually match you based on your preferences, to the five or six houses that are best for you."

Houston-based Entera has grown as the platform loads more and more data for its users to engage with.

Luther Birdzell, CEO and founder of OAG Analytics

Courtesy of OAG Analytics

Luther Birdzell always knew he wanted to run his own company, but the software and analytics professional worked in various industries before realizing that oil and gas had a huge opportunity for savings using analytics. He founded OAG Analytics in 2013 to help provide a solution for these companies.

"When I founded OAG Analytics, our mission then — and still is today — was to build a platform for the upstream oil and gas industry that enables them to manage their data, introduces world-class machine learning in minutes without having to write a single line of code, and allow them to run simulations on the resulting analysis," Birdzell says.

The company has grown to 25 employees and tripled its revenue last year. The team is forecasting another year of high grow for 2019.


Houston-based Moleculin has three different oncology technologies currently in trials. Getty Images

Immunotherapy and personalized medicine get all the headlines lately, but in the fight against cancer, a natural compound created by bees could beat them in winning one battle.

In 2007, chairman and CEO Walter Klemp founded Moleculin Biotech Inc. as a private company. The former CPA had found success in life sciences with a company that sold devices for the treatment of acne. That introduction into the field of medical technology pushed him toward more profound issues than spotty skin.

"Coincidentally, the inventor of that technology had a brother who was a neuro-oncologist at MD Anderson," Klemp recalls.

The since-deceased Dr. Charles Conrad slowly lured Klemp into what he calls the "cancer ecosphere" of MD Anderson. In 2016, the company went public. And it looks like sooner rather than later, it could make major inroads against some of the toughest cancers to beat.

Klemp observed that while Houston has the world's largest medical center, "the tragic irony" is that other cities have far more biotech money ready to be invested.

"The Third Coast is really starved for capital," he says. "What drew me into this was I was one of the few entrepreneurs that lived here that knew the ropes in terms of tapping into East and West Coast capital structures and could make that connection for them."

The company has three core technologies currently being tested with some success, but the most promising is called WP1066, named for researcher Waldemar Priebe, "a rock star" in his native Poland, according to Klemp, who works at MD Anderson. Though Priebe came to the U.S. in the 1980s, he is still an adjunct professor at the University of Warsaw and conducts some of his trials in Poland because it's easier to get grant money there.

WP1066 uses propolis, a compound of beeswax, sap and saliva that bees produce to seal small areas of their hives, as a base. The molecular compound that Priebe discovered affects STAT3 (signal transducer and activator of transcription), a transcription factor that encourages tumor development. In short, the active compound in WP1066 both downregulates the STAT3, a long-time Holy Grail in the cancer research world, and directly attacking the tumor, but also quieting T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

WP1066 is demonstrating drug-like properties in trials at MD Anderson on glioblastoma, the aggressive brain cancer that recently took the life of the hospital's former president, John Mendelsohn, as well as John McCain and Beau Biden. It is also being tested against pancreatic cancer, one of the most virulent killers cancer doctors combat.

Priebe also created Annamycin, named for his oldest daughter, a first-line chemotherapy drug that fights Acute Myeloid Leukemia without the cardiotoxicity that can damage patients' hearts even as they beat their cancer.

WP1122 uses yet another mechanism to fight cancer.

"Most people don't know that morphine is essentially a modified version of heroin," Klemp explains.

The difference between the poppy-based drugs? Heroin can cross the blood-brain barrier. It's described as the dicetyl ester of morphine. WP1122 is the dicetyl ester of 2DG (2-Deoxyglucose), a glycolysis inhibitor, which works by overfilling tumor cells with fake glucose so that they can't consume the real glucose that makes them grow.

"The theory is, we could feed you so full of junk food that eventually you'd starve to death," Klemp elucidates. It can cross the blood-brain barrier and is metabolized slowly, meaning that it can be made into a drug in a way that 2DG cannot.

What's impressive about Moleculin is its diversity of drugs. Most companies have one drug that gets all or most of the attention. Moleculin has strong hopes for all three currently in trials.

"It's essentially multiple shots on the goal," says executive vice president and CFO Jonathan Foster.

Moleculin has 13 total employees, five of whom are based in Houston. An office in the Memorial Park area serves as a landing pad for employees and collaborators from around the world to get their work done when in Space City. The virtual office set-up works for the company because experts can stay in their home cities to get their work done. And that work is on its way to saving scores of lives.